Eli Lilly’s Soaring Price Target: Analyst Sees Major Upside in Obesity Pipeline

The investment case for Eli Lilly continues to strengthen, even after the pharmaceutical giant surpassed a $1 trillion market valuation. A substantial new price target from Bernstein analysts is generating significant buzz, highlighting a previously underappreciated asset in the competitive weight-loss drug market. This development raises a pivotal question: is the company poised for its next major growth phase, or is the current market enthusiasm becoming excessive?

Eli Lilly is demonstrating its ambition to be more than a single-product company through recent clinical and strategic moves. The firm announced advancements in its oncology portfolio and type 1 diabetes treatments within the past day. Simultaneously, management is executing an interesting strategic shift: replacing current Read more...